-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KGDGVR6v+LazKyN+LrPkkpaYF0ToIjOP3n5c2LEYWE4AQxz7LHRzUS1aEbLi5nTH Qxqv5tuBZ/LGIwRcAiFUOA== 0001203928-09-000005.txt : 20090804 0001203928-09-000005.hdr.sgml : 20090804 20090804103556 ACCESSION NUMBER: 0001203928-09-000005 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506 FILED AS OF DATE: 20090804 DATE AS OF CHANGE: 20090804 EFFECTIVENESS DATE: 20090804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OTHERA PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0001203928 IRS NUMBER: 752983920 STATE OF INCORPORATION: PA FISCAL YEAR END: 1209 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-49840 FILM NUMBER: 09982081 BUSINESS ADDRESS: STREET 1: 730 SPRINGDALE DRIVE CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 484-879-2800 MAIL ADDRESS: STREET 1: 730 SPRINGDALE DRIVE CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: OTHERA PHARMACEUTICALS INC DATE OF NAME CHANGE: 20021106 D/A 1 primary_doc.xml X0502 D/A LIVE 0001203928 OTHERA PHARMACEUTICALS, INC 730 SPRINGDALE DRIVE EXTON PA 19341 484-879-2800 OTHERA PHARMACEUTICALS INC PENNSYLVANIA Corporation true David S. Joseph c/o Othera Pharmaceuticals, Inc. 730 Springdale Drive Exton PA 19341 Executive Officer Director Thomas R. Morse c/o Liberty Venture Partners 2005 Market Street, Suite 2040 Philadelphia PA 19103 Director Hans Mueller c/o hmConsulting 1802 Chestnut Hollow Lane West Chester PA 19382 Director Brian G. Murphy c/o New Spring Ventures, L.P. 500 North Gulph Road, Suite 500 King of Prussia PA 19406 Director Katherine Crothall c/o Othera Pharmaceuticals, Inc. 730 Springdale Drive Exton PA 19341 Director Rami Elghandour c/o Johnson and Johnson Dev. Corp. 410 George Street New Brunswick NJ 08901 Director Biotechnology No Revenues 06 true 0001203928-09-000004 2008-10-10 false true true true false 50000 10769994 10619994 150000 Further proceeds include exercise price of Warrants to be issued at a later date, which exercise price is not yet determinable, and Warrants to purchase shares of Series C Convertible Preferred Stock at an aggregate exercise price of $1,769,994. false 26 0 0 350000 true false OTHERA PHARMACEUTICALS, INC Philip Heifetz Philip Heifetz Vice President 2009-08-04 -----END PRIVACY-ENHANCED MESSAGE-----